Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grapefruit juice could change how depression drug works

NCT ID NCT06726382

Knowledge-focused Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested how grapefruit juice and the HIV drug cobicistat affect levels of esketamine, a depression treatment, in 12 healthy volunteers. Participants received esketamine as a nasal spray or oral liquid, with or without these substances. Researchers measured drug levels in the blood over 24 hours to see if these interactions matter.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Esketamine (nasal spray and oral solution), cobicistat, grapefruit juice
What this could lead to
If successful, this could help doctors understand how to adjust esketamine doses when taken with common substances like grapefruit juice, potentially making treatment more affordable or effective.
What could go wrong
This is a very small, early-phase study in healthy volunteers, not patients. It only measures drug levels, not actual treatment outcomes, so results may not apply to real-world depression care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Dec 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * signed consent * age 18-45 years * healthy * no indications of substance abuse * Accepted results from laboratory tests (blood hemoglobin, basic blood count and blood platelets, alanine aminotransferase, alkaline phosphatase, glutamyl transferase, creatinine, plasma potassium and sodium). Negative pregnancy test result (serum human chorionic gonadotropin) for women. * no significant abnormalities in the ECG * systolic blood pressure 140 mmHg-100 mmHg * heart rate ≥50/minute Exclusion Criteria: * significant illness * less than 3 months since the last clinical trial * less than 3 months after donating blood * significant overweight/poor veins * BMI below 18.5 kg/m2 * past or present mood disorder or suicidality * substance abuse * systolic blood pressure below 100 mmHg or above 140 mmHg * heart rate \<50/minute * conduction disorder or other significant abnormality in the ECG * smoking * regular medication (including e-pills and other preparations containing estrogens) * pregnancy or its planning or breastfeeding * hypersensitivity to investigational drugs or excipients of medicinal products * use of natural products (such as St. John's wort)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug interactions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug interactions Food-drug interaction

Contacts and locations

Locations

  • Department of Clinical Pharmacology

    Helsinki, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.